Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Andreas Grassauer Ph.D. | Co-Founder, Chairman of Management Board & CEO | 300.3k | -- | 1969 |
| Ms. Eva Prieschl-Grassauer Ph.D. | Co-Founder, Vice Chairwoman of Management Board & Chief Scientific Officer | 292.7k | -- | 1968 |
| Mr. Pascal Schmidt | CFO & Member of Management Board | 303.6k | -- | 1972 |
| Ms. Stephanie Kniep | Head of Investor Relations | -- | -- | -- |
Marinomed Biotech AG
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 36
Description
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. The company operates through Virology, Immunology, and Other segments. Its products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
Corporate Governance
Upcoming Events
November 21, 2024 at 10:59 AM UTC
Marinomed Biotech AG Earnings Date
Recent Events
Recent Events Information Not Available